

COMMONWEALTH OF MASSACHUSETTS

SUFFOLK COUNTY

BOARD OF REGISTRATION
IN PHARMACY

In the Matter of)
CVS # 114)
DS2821)

PHA-2017-0180

CONSENT AGREEMENT FOR REPRIMAND


The Massachusetts Board of Registration in Pharmacy ("Board") and CVS # 114 ("Pharmacy" or "Licensee"), a pharmacy licensed by the Board, DS2821, do hereby stipulate and agree that the following information shall be entered into and become a permanent part of the Pharmacy's record maintained by the Board:


1. The Pharmacy acknowledges the Board opened a Complaint against its Massachusetts pharmacy license related to the conduct set forth in Paragraph 2, identified as Docket Number PHA-2017-0180 ("Complaint").
2. The Board and the Pharmacy acknowledge and agree to the following facts:
 - a. During an inspection on December 28, 2016, a Board investigator observed the Pharmacy, on multiple occasions, dispensed inordinate quantities of methylphenidate 20 mg tablets and amphetamine salts 30 mg tablets to Patient A, in violation of M.G.L. c. 94C, § 19(a), 247 CMR 6.07(1)(j), and 21 CFR § 1306.
 - b. Specifically, the Pharmacy filled multiple prescriptions written for:
 - i. Methylphenidate 20 mg tablets, 25 tablets (500 mg) per day; and
 - ii. Amphetamine salts 30 mg tablets, 2 tablets (60 mg) per day.
3. The Pharmacy acknowledges that the facts described in Paragraph 2 warrant disciplinary action by the Board under M.G.L. c. 12, §§ 42A & 61 and 247 CMR 10.03(1)(a), (b), (v), & (x).
4. The Pharmacy agrees that the Board shall impose a REPRIMAND on its license based on the facts admitted in Paragraph 2, effective as of the date on which the Board signs this Agreement ("Effective Date").
5. The Board acknowledges the receipt of documentation demonstrating the Pharmacy implemented a corrective action plan that includes the following:


- a. Appropriate dosing regimens for methylphenidate;
 - b. Appropriate dosing regimens for amphetamine salts;
 - c. Treatments for narcolepsy; and
 - d. Pharmacists corresponding responsibility.
6. The Pharmacy and the Board acknowledge the Board's receipt of said documentation was a precondition to be met before the Board entered into this Agreement.
 7. The Board agrees that in return for the Pharmacy's execution and successful compliance with all the requirements of this Agreement, the Board will not prosecute the Complaint.
 8. The Pharmacy understands that it has a right to formal adjudicatory hearing concerning the Complaint and that during said adjudication the Pharmacy would possess the right to confront and cross-examine witnesses, to call witnesses, to present evidence, to testify on its own behalf, to contest the allegations, to present oral argument, to appeal to the courts, and all other rights as set forth in the Massachusetts Administrative Procedures Act, M.G.L. c. 30A, and the Standard Adjudicatory Rules of Practice and Procedure, 801 CMR 1.01 *et seq.* The Pharmacy further understands that by executing this Agreement the Pharmacy is knowingly and voluntarily waiving its right to a formal adjudication of the Complaint.
 9. The Pharmacy acknowledges that it has been at all times free to seek and use legal counsel in connection with the Complaint and this Agreement.
 10. The Pharmacy acknowledges that after the Effective Date, the Agreement constitutes a public record of disciplinary action by the Board subject to the Commonwealth of Massachusetts' Public Records Law, M.G.L. c. 4, § 7. The Board may forward a copy of this Agreement to other licensing boards, law enforcement entities, and other individuals or entities as required or permitted by law.
 11. The Pharmacy understands and agrees that entering into this Agreement is a voluntary and final act and not subject to reconsideration, appeal or judicial review.

CVS # 114
DS2821
PHA-2017-0180

12. The individual signing this Agreement certifies that he/she is authorized to enter into this Agreement on behalf of the Pharmacy, and that he/she has read this Agreement.


Witness (sign and date)
7/25/17


(sign and date)
Jeffrey Sinko, RPh, JD
(print name)


David Sencabaugh, R. Ph.
Executive Director
Board of Registration in Pharmacy

8/17/18
Effective Date of Reprimand Agreement

Fully Signed Agreement Sent to Licensee on 8/17/18 by Certified Mail
No. 7017 0530 0000 3482 5674

CVS# 114
DS2821
PHA-2017-0180